Ectasia

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, May 1, 2023
General Health, Medical Devices, Health, Pharmaceutical, Optical, GKOS, Glaucoma, Collagen, Refractive surgery, Corneal ectatic disorders, ASCRS, Retina, American Society of Cataract and Refractive Surgery, Corporation, Art, Physician, Cataract, Borat Subsequent Moviefilm, Society, NYSE, Pharmaceutical industry, Keratoconus, Ectasia

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.
  • Glaukos will be exhibiting onsite at booth #1237.
    iStent inject® Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Open-Angle Glaucoma: Long-Term Results
    10-Year Follow-up for Collagen Cross-Linking in Keratoconus and Ectasia: Comparison of Outcomes with Subsequent Topography-Altering Surgery
    Customized Transepithelial Cross-Linking for Keratoconus: 2-Year Follow-up
    Keratoconus State of the Art: New Cutting-Edge Treatments for Corneal Ectasia (IC-105)
    The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.
  • All educational content of the ASCRS annual meeting is planned by its program committee.
  • ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

Insights on the Global Tumor Ablation Industry to 2027 - Drivers, Restraints, Opportunities & Threats - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Surgery, Health, Oncology, Medical specialties, RTT, Medicine, Clinical medicine, Gastric antral vascular ectasia, Ablation, Pancreatic cancer, Cholangiocarcinoma, Cancer, Ectasia, Radiofrequency ablation, Targeted radiofrequency ablation

The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Tumor Ablation market accounted for $394.66 million in 2018 and is expected to reach $1,253.33 million by 2027 growing at a CAGR of 13.7% during the forecast period.
  • Tumor ablation is a minimally invasive image-guided technique used in the treatment of the tumors in the liver, kidney, soft tissue and bone.
  • Tumor ablation has primarily been used for the treatment of oesophagal squamous cell dysplasia, gastric antral vascular ectasia, radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia.